Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Butowski, Nicholas; Colman, Howard; de Groot, John; Omuro, Antonio; Nayak, Lakshmi; Y. Wen, Patrick; F. Cloughesy, Timothy; Marimuthu, Adhirai; Haidar, Sam; Perry, Arie; T. Huse, Jason; J. Phillips, Joanna; L. West, Brian; B. Nolop, K.; H. Hsu, Henry; L. Ligon, Keith; M. Molinaro, Annette; D. Prados, Michael

doi:10.1093/neuonc/nov245

Public

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Published in Neuro-Oncology • Oct 8, 2015

Authors:

Nicholas Butowski

Howard Colman

John de Groot

Abstract

BACKGROUND: The colony stimulating factor 1 receptor (CSF1R) ligands, CSF1 and interleukin-34, and the KIT ligand, stem cell factor, are expressed in glioblastoma (GB). Microglia, macrophages, blood vessels, and tumor cells also express CSF1R, and depletion of the microglia reduces tumor burden and ...

Subject

Cmax

Pharmacokinetics

Pharmacodynamics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!